Compare Sanofi SA (SNY) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs ProShares UltraPro S&P500 — how do they compare? Sanofi SA trades at $43.62 (market cap $104.30B), while ProShares UltraPro S&P500 trades at $154.83. The key difference: Sanofi SA pays a 5.55% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | UPRO | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $155.10 |
52-Week Low | $41.33 | $89.29 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
UPRO, a leveraged ETF tracking the S&P 500, trades at $154.9 with a slight 0.06% decline. Technical indicators show a bullish trend with strong moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. Support lies at $152, with resistance at $155. Recent news highlights institutional buying and S&P 500 volatility amid inflation data and AI-driven earnings optimism.
The outlook for UPRO hinges on S&P 500 momentum, with bullish technicals but overbought risks. Upside potential exists if the index breaks resistance, but high leverage amplifies losses during pullbacks. Key risks include market volatility, inflation concerns, and stretched valuations. Investors should weigh the ETF's leveraged structure against broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
